Summary:
- The FDA has approved a new medication called Icotyde (icotrokinra) for the treatment of moderate to severe plaque psoriasis in adults.
- Icotyde is the first and only FDA-approved first-line systemic treatment for plaque psoriasis that works by targeting a specific protein in the body that causes inflammation.
- This new treatment option provides an alternative for patients who may not respond well to or cannot tolerate other psoriasis medications, offering hope for improved skin health and quality of life.